Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 25877855

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 May
First author
Tabernero J

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):476-7. doi: 10.1016/S1470-2045(15)70169-5.
    note
    Source null
    related pmid
    25877856
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Jul;12(7):373. doi: 10.1038/nrclinonc.2015.80.
    note
    Source null
    related pmid
    25940984
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70273-1.
    note
    Source null
    related pmid
    26065608
    relationship
    Erratum in

Authors and identifiers

  1. name
    Tabernero J
    type
    Author
  2. name
    Yoshino T
    type
    Author
  3. name
    Cohn AL
    type
    Author
  4. name
    Obermannova R
    type
    Author
  5. name
    Bodoky G
    type
    Author
  6. name
    Garcia-Carbonero R
    type
    Author
  7. name
    Ciuleanu TE
    type
    Author
  8. name
    Portnoy DC
    type
    Author
  9. name
    Van Cutsem E
    type
    Author
  10. name
    Grothey A
    type
    Author
  11. name
    Prausová J
    type
    Author
  12. name
    Garcia-Alfonso P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tabernero J
    type
    Author
  2. name
    Yoshino T
    type
    Author
  3. name
    Cohn AL
    type
    Author
  4. name
    Obermannova R
    type
    Author
  5. name
    Bodoky G
    type
    Author
  6. name
    Garcia-Carbonero R
    type
    Author
  7. name
    Ciuleanu TE
    type
    Author
  8. name
    Portnoy DC
    type
    Author
  9. name
    Van Cutsem E
    type
    Author
  10. name
    Grothey A
    type
    Author
  11. name
    Prausová J
    type
    Author
  12. name
    Garcia-Alfonso P
    type
    Author
bibliography ids
  1. nci-bib-8229118762a9f955a14ddbd3
book metadata
content sha256
f6723692196be6f60b154351b927f03c4f824d7c1938f6853ad5122c52bae3a5
document type
citation
dois
  1. 10.1016/S1470-2045(15)70127-0
electronic publication date
display
2015 Apr 12
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25877855
immutable id
pubmed:25877855@f6723692196be6f60b154351b927f03c4f824d7c1938f6853ad5122c52bae3a5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
499-508
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):476-7. doi: 10.1016/S1470-2045(15)70169-5.
    note
    Source null
    related pmid
    25877856
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Jul;12(7):373. doi: 10.1038/nrclinonc.2015.80.
    note
    Source null
    related pmid
    25940984
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2015 Jun;16(6):e262. doi: 10.1016/S1470-2045(15)70273-1.
    note
    Source null
    related pmid
    26065608
    relationship
    Erratum in
outcomes validated
false
pmid
25877855
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
e64f2a760d7ae89c7b139770c0f4660db0d0573c0226e8166484acf258616371
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 May
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25877855/
title
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Preserved source evidence · Independent clinical review pending · Not medical advice